Ozoralizumab

N/A

Report date: 2023/02/01 17:30:14
First In Class

Base Information

Drug NameOzoralizumab
Drug Alias NameナノゾラNanozoraPF-5230896PF-05230896TS-152 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor α inhibitorsSerum albumin binders
TargetsTumor necrosis factor αSerum albumin
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/09/26
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesEddingpharm BvTaisho Pharmaceutical Co Ltd
Inactive CompaniesAblynx Nv
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG